Clinical Trials Logo

Primary Bile Acid Malabsorption clinical trials

View clinical trials related to Primary Bile Acid Malabsorption.

Filter by:
  • None
  • Page 1

NCT ID: NCT01585025 Completed - Chronic Diarrhoea Clinical Trials

Obeticholic Acid in Bile Acid Diarrhoea

OBADIAH1
Start date: April 2012
Phase: Phase 2
Study type: Interventional

The investigators propose to develop studies of obeticholic acid (OCA) in patients with bile acid diarrhoea. OCA is a semisynthetic bile acid, also known as 6αethylchenodeoxycholic acid or INT747,and is a potent farnesoid X receptor (FXR) agonist. Preliminary data suggests that patients with bile acid diarrhoea have impaired production of the ileal hormone Fibroblast Growth Factor 19 (FGF19). FGF19 is stimulated by FXR agonists, and regulates bile acid synthesis. This study is a pilot, proof-of-concept, open-label study to investigate whether OCA can stimulate FGF19 in bile acid diarrhoea patients to provide a safe and effective treatment.